

Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort



Heribert Knechten', Christoph Stephan², Michael Walzmann³, Jason Brunetta', Benoit Trottier', Claudine Duvivier', Berend van Welzen⁴, Frank Mack⁹, Harout Tossonian⁴, David Thorpe⁴¹, Almudena Torres Comejo⁴², Andrea Maronglu¹¹, Rafael Curbelo⁴⁴

PZB (Pratice Center Blondelstraße), Aachen, Germany, "University Hospital Franklut, Moderal Christin II, Franklut, Moderal Christin II, Franklut, Montreal, Camany, "Paxie Walker and Moderal Christin Control and Activity", and the Control of C

Introduction and Objective

- The <u>BIC</u>tegravir <u>Single Tablet Regimen</u> (BICSTaR) study is an ongoing, 2-year, multi-country, observational cohort study that plans to enrol at least 1400 PLWH who receive B/F/TAF in routine clinical practice
- In addition to evaluating the effectiveness and safety of B/F/TAF, patient-reported outcomes (PROs) are directly completed by participants to capture aspects of health status, such as mental/physical health, health-related quality of life (HRQoL), and treatment satisfaction
- We present preliminary PRO data that were prospectively collected in ART-naïve (TN) and ART-experienced (TE) participants after 12 months of receiving B/F/TAF as an initial or switch regimen

Methods

- This pre-specified, descriptive PRO analysis included a subset of participants from Germany, Canada, France, and the Netherlands who completed PRO questionnaires at both baseline and Month 12 ('PRO analysis population')
- PROs collected were:

Table 1. PRO tools

Domain	PRO tool	Visits	Evaluation
Quality of life (HRQoL) Mental (MCS) Physical (PCS)	SF-36	Baseline Month 12	Median SF-36 summary score
HIV ART-related symptoms*	HIV-SI	Baseline Month 12	% Participants reporting 'bothersome symptoms'
HIV treatment satisfaction (only TE)	HIVTSQs HIVTSQc	Baseline Month 12	Median total score change

"Symptoms were dichotomised into 'not bothersome' (scores of 0 or 1) or 'bothersome' (scores of 2, 3, or 4). Th overall bothersome symptom count at baseline was generated by counting the number of individual symptoms scored as bothersome

ART, antiretroviral-reatment: BH/TAF, bickegravir/iranticiabanetenc/ovir alafanamide; HUTSOc, HIV Treatment Satisfaction Questionnaire – charge; HIVTSOs, HIV Treatment Satisfaction Questionnaire – status; HIV-SI, HIV Saymonn Index; MCS, mental component score; PCS, physicial component score; PLWH, people living with HIV, S

Results

Overall study population baseline characteristics are:

Table 2.		
	TN, n=84	TE, n=429
Male, n (%)	76 (91)	392 (91)
Age, years, median (Q1–Q3) Age ≥50 years, n (%)	38 (29–48) 20 (24)	49 (40–56) 209 (49)
White, n (%)	71 (85)	387 (90)
Comorbidities None, n (%) 1-2, n (%) ≥3, n (%)	41 (49) 25 (30) 18 (21)	108 (25) 168 (39) 153 (36)
Neuropsychiatric disorder, n (%) Hyperlipidaemia, n (%) Hypertension, n (%)	16 (19) 7 (8) 5 (6)	122 (28) 87 (20) 87 (20)
Any comedication received, n (%)	35 (45)	256 (60)
HIV-1 RNA, log ₁₀ cp/mL, median (Q1, Q3) <50 cp/mL, n (%) >100,000 cp/mL, n (%)	4.77 (3.94, 5.18) 0 (0) 30/82 (37)	1.59 (1.28, 1.59) 362/393 (92) 2/393 (1)
CD4 count*, cells/µL, median (Q1, Q3) CD4 <200 cells/µL, % CD4 <350 cells/µL, %	427 (244, 581) 21 38	668 (455, 877) 4 14
CD4/CD8 ratio, median (Q1, Q3)	0.4 (0.3, 0.6)	0.8 (0.6, 1.2)


"Sample size of 78 for TN and 382 for TE cp, copies; Q, quartile; TE, treatment-experienced; TN, treatment-naïve

Table 3. PRO Analysis Population Baseline Characteristics


Overall sample (N=513)		SF-36 (n=221)		HIV-SI (n=250)	
TN n=84	TE n=429	TN n=38	TE n=183	TN n=43	TE n=207
38 (29–48)	49 (40–56)	37 (30, 44)	48 (40, 55)	36 (29, 44)	49 (40, 55)
20 (24%)	209 (49%)	8 (21%)	79 (43%)	9 (21%)	96 (46%)
76 (91%)	392 (91%)	34 (90%)	170 (93%)	39 (91%)	194 (94%)
71 (85%)	387 (90%)	33 (87%)	167 (91%)	37 (86%)	188 (91%)
	(N=8 TN n=84 38 (29–48) 20 (24%) 76 (91%)	(N=513) TN TE n=84 n=429 38 (29-48) 49 (40-56) 20 (24%) 209 (49%) 76 (91%) 392 (91%)	(N=513) (n=22) TN TE n=38 n=84 n=429 n=38 38 (29-48) 49 (40-56) 37 (30, 44) 20 (24%) 209 (49%) 8 (21%) 76 (91%) 392 (91%) 34 (90%)	Image: Number Num Number Number Number Number Number Number Number Num	Image: Non-State (n=24) (n=24) TN TE TN TE n=84 n=429 n=38 n=183 n=43 38 (29-48) 49 (40-56) 37 (30, 44) 48 (40, 46) 48 (40, 40) 20 (24%) 200 (49%) 8 (21%) 79 (43%) 9 (21%) 76 (91%) 392 (91%) 34 (90%) 170 (93%) 39 (91%)


- In the PRO analysis population, 221 and 250 PLWH completed the SF-36 and HIV-SI questionnaires, respectively, at both Baseline and Month 12
- The PRO analysis population was comparable to the overall study population in terms of age, gender, and ethnicity

Results Cont.




- Physical component scores (PCS) were high at baseline in both TN and TE participants, and remained stable after 12 months.
- In TN participants, a numerically higher mental component score (MCS) was observed at 12 months; the score remained stable in TE participants






 In participants with neuropsychiatric disorders at baseline, a numerically higher mental health component score (MCS) was observed after 12 months on B/F/TAF


Figure 3. HIV-SI 'Bothersome' Symptoms* in TN Participants (n=43)



- For TN, the overall median bothersome symptom count at baseline was 6 (IQR 2, 9); this decreased to 3 (2, 7) at Month 12
- A trend towards a decrease in the frequency of CNSrelated bothersome symptoms was observed in TN participants after 12 months



- For TE, t=he overall median bothersome symptom count at baseline was 3 (IQR 0, 6); this did not change at Month 12
- Overall, small numerical differences were observed in bothersome symptoms in TE participants at Month 12



 Baseline HIVTSQs total score was high in TE participants with numerically higher scores observed following switch to B/F/TAF at Month 12, with an HIVTSQc median total score change of 20

Discussion

HRQoL (SF-36)

- In TN participants initiating ART with B/F/TAF, a numerical increase in the HRQoL mental component score was observed after 12 months, while the physical component remained stable
- In TE participants, both mental and physical components remained stable and no changes were observed
- HIV ART-related symptoms (HIV-SI)
- In TN participants, a trend towards a decrease in frequency of CNS-related bothersome symptoms was observed after 1 year on B/F/TAF
- Treatment satisfaction (HIVTSQs and HIVTSQc)
 A numerical increase in treatment satisfaction was observed among participants who switched to B/F/TAF

Conclusions

 These data support the favourable profile of B/F/TAF in a real-world setting using selfreported outcomes from treatment-naïve and treatment-experienced PLWH who had a high prevalence of comorbidities at baseline

Disclosures

- **HK** has acted as a consultant for Gilead;
- CS has acted as consultant for AbbVie, Gilead, Hexal AG, Janssen-Cilag, MSD and received travel grants from Gilead, Janssen-Cilag and MSD;
- MW has acted as a board member for ViiV;
- JB has participated in advisory boards for Gilead, Merck and ViiV; and reports travel grants from Gilead and ViiV and speaker bureaus, speaker fees and consultancy for Gilead;
- BT has participated in advisory boards for Gilead, Merck and ViiV; and reports travel grants from Gilead and ViiV;
- FB reports travel grants from Gilead and ViiV and speaker bureaus, speaker fees and consultancy for Gilead, ViiV, Janssen. MSD:
- CD has participated in advisory boards for Gilead, and ViiV and reports travel grants from Merck, Gilead and ViiV and speaker fees and consultancy for Gilead and ViiV;
- BvW has nothing to disclose.
- FM, HT, DT, ATC, AM, and RC are employees and shareholders of Gilead.

Acknowledgments

We thank all study participants, study sites and investigators.

The BICSTAR study is sponsored by Gilead Sciences HV3, HV Synpton Index PUWI, popeling with HV Q, quartic Sr-30, 38-bits Biorl Fam Heath Survy; TE submitted-superiord. The traditionationals All cardination allowage IFTA being without disable and cardination. CMR, center nances system; HVTBQ: HVTButtment Sa